The purpose of this study was to determine whether acetylation of the sulfonamide drugs in the human body could be prevented by substituting a simple alkyl radicle on the amino group of the drug without otherwise impairing the efficiency of its therapeutic action. Methyl and dimethyl substituted sulfanilamides were made and investigated from a pharmacological and therapeutic viewpoint.
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Because of the theoretical implications these drugs were tested for their action in vitro. Although it has been stated that alkyl substituted compounds of this nature are less active in vivo2'4 than sulfanilamide, the only compounds that Dimethylsulfanilamide was synthesized by the reactions described above. About 60 gm. of vacuum-distilled dimethylaniline was added to 165 cc. of redistilled chlorosulfonic acid. The reaction was slow and incomplete even after 36 hours at 900 C. Dimethylaminobenzenesulfonylchloride has a brilliant yellow color and melts at 1060 C., as described by Schweitzer.7 Dimethylsulfanilamide crystallizes in leaflets melting at 2130 C. The over-all yield was less than 5 per cent. Nitrogen determination showed (C8HI202N2S) 13.7 per cent; theoretical value, 13.7 per cent. Solubility in water at 250 C. 13 mg. %. (Hydrolysis of the sulfonyl chloride yielded a free acid from which the barium salt could be obtained as needle-shaped crystals described by Meisenheimer.') Pharmacological properties Although the relative toxicity of the compounds was not determined, four of five mice injected subcutaneously with methylsulfanilamide (5 gm. per kg. of body weight) suspended in saline and acacia succumbed to convulsions shortly after the injection. No toxic effects were noted from therapeutic doses.
The blood level of diazotizable substances (expressed as sulfanilamide) was determined in patients and in pooled blood from several mice given the drugs. (See Table 1 .) between 300 and 500 organisms per cubic centimeter. The broth, bacteria, and drug mixtures were incubated at 390 C. in the case of the hemolytic streptococcus C 203 and the type I pneumococcus, and at 410 C. for cultures of Streptococcus viridans. If "no growth" was observed after incubation for 48 hours, 1.0 cc. of the mixture was subcultured into 9 cc. of blood-broth and incubated for 72 hours to see if the original mixture was "sterile." The results of three experiments done in duplicate are summarized in Table 3 . The inconstant results obtained with the dimethyl substituted compound may be due to the fact that all of it did not go into solution in the broth mixture. No diazotizable substance (sulfanilamide) could be detected in the broth cultures that were sterilized by the methyl and dimethyl sulfanilamides.
Discussion
Although the initial objective of these experiments was not attained, certain pertinent observations may be made. The introduction of methyl radicles into the amino group of sulfanilamide renders it less soluble, the dimethyl substituted compound being less soluble than is the monomethyl compound. Although the methyl substituted sulfanilamides are stable in boiling aqueous, acidic, or alcoholic solutions, they are promptly demethylated in the human body and in the mouse, yielding presumably sulfanilamide. Methylsulfanilamide is therapeutically active in mouse infection with the beta hemolytic streptococcus. Methylsulfanilamide is bactericidal to the hemolytic streptococcus when tested in vitro, although no break-down to sulfanilamide was found. Neither of the methyl substituted compounds had an inhibitory effect upon the pneumococcus or Streptococcus viridans. Summary P(acetylmethylamino)benzenesulfonylchloride, p(acetylmethylamino)benzenesulfonamide, p(methylamino)benzenesulfonamide (N4methylsulfanilamide), p(dimethylamino)benzenesulfonylchloride, and p(dimethylamino)benzenesulfonamide (N4dimethylsulf-anilamide) have been synthesized and characterized.
Methylsulfanilamide is an active chemotherapeutic agent against the beta hemolytic streptococcus. Dimethyl and methyl sulfanilamides are demethylated when administered to the human being or to the mouse. Methylsulfanilamide is streptococcidal in vitro.
